Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study.

Recently, an EARCO ERS Clinical Research Collaboration analysis that investigated the impact of COVID-19 on patients with severe AATD (PiZZ, PiSZ, or rare variants with an equivalent serum A1AT level < 60 mg/dL) [ 18 ] showed that while a poor outcome was more frequent in PiZZ compared with PiSZ, this did not reach statistical significance; non-respiratory comorbidities were more strongly associated with a poor outcome than genotype, baseline FEV1, or oxygen saturation.

also in 111,027 other papers